文献速递认知障碍与痴呆

生物学定义阿尔茨海默病与年龄、性别、APOE ε4及认知障碍的关系

Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment.
PubMed 文献 · Neurology · 2020-12-21

本研究纳入认知未受损老年人166例、遗忘型轻度认知障碍患者77例和 probable AD 痴呆患者62例,均接受淀粉样蛋白PET和tau PET评估。临床 probable AD 痴呆与生物学定义AD的阳性预测值为85.2%,认知未受损者中7.88%同时淀粉样蛋白和tau PET阳性。生物学定义AD频率随年龄增长和APOE ε4携带而升高。

要点

  • 临床 probable AD 痴呆与生物学定义AD的一致性强但不完全,阳性预测值85.2%。
  • 认知未受损老年人中7.88%同时淀粉样蛋白和tau PET阳性,生物学定义AD并不罕见。
  • 生物学定义AD频率随年龄增长及APOE ε4携带(单拷贝和双拷贝)而升高。

核心结论

  • 临床 probable AD 痴呆与淀粉样蛋白和tau PET双阳性之间一致性强但不完全。
  • 生物学定义AD在认知未受损老年人中并不罕见,且异常tau PET几乎仅见于淀粉样蛋白PET异常者。
  • 即使经痴呆专科医生系统评估,仍会系统性低估生物学定义AD及相关实体的频率。

研究设计与样本

  • 前瞻性队列研究,纳入认知未受损老年人166例、遗忘型轻度认知障碍患者77例和 probable AD 痴呆患者62例。
  • 所有受试者接受痴呆专科医生和神经心理学家评估,以及[18F]AZD4694淀粉样蛋白PET和[18F]MK6240 tau PET检查。
  • 根据AD生物标志物谱对个体进行分组,评估临床诊断对生物学定义AD的阳性预测值,并用逻辑回归分析生物标志物谱频率与年龄、性别、APOE ε4的关系。

主要发现

  • 临床 probable AD 痴呆对生物学定义AD的阳性预测值为85.2%。
  • 认知未受损老年人中7.88%同时淀粉样蛋白PET和tau PET阳性。
  • 生物学定义AD频率随年龄增长而升高(OR 1.14;p < 0.0001)。
  • APOE ε4单拷贝携带者生物学定义AD频率升高(OR 3.82;p < 0.0001),双拷贝携带者升高更明显(OR 17.55;p < 0.0001)。
  • 异常tau PET几乎仅见于淀粉样蛋白PET异常的个体。

关键数值与推荐

  • 生物学定义AD指淀粉样蛋白PET和tau PET均异常。
  • 临床 probable AD 痴呆中85.2%为生物学定义AD。
  • 认知未受损老年人中7.88%为生物学定义AD。

临床怎么用

  • 在记忆门诊中,应认识到临床诊断 probable AD 痴呆与生物学定义AD并非完全一致。
  • 对认知未受损老年人,需关注生物学定义AD的可能性,尤其在高龄或APOE ε4携带者中。
  • tau PET异常几乎仅见于淀粉样蛋白PET异常者,支持AD生物标志物谱的层级关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the frequency of biologically defined Alzheimer disease (AD) in relation to age, sex, APOE ε4, and clinical diagnosis in a prospective cohort study evaluated with amyloid-PET and tau-PET. METHODS: We assessed cognitively unimpaired (CU) elderly (n = 166), patients with amnestic mild cognitive impairment (n = 77), and patients with probable AD dementia (n = 62) who underwent evaluation by dementia specialists and neuropsychologists in addition to amyloid-PET with [18F]AZD4694 and tau-PET with [18F]MK6240. Individuals were grouped according to their AD biomarker profile. Positive predictive value for biologically defined AD was assessed in relation to clinical diagnosis. Frequency of AD biomarker profiles was assessed using logistic regressions with odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: The clinical diagnosis of probable AD dementia demonstrated good agreement with biologically defined AD (positive predictive value 85.2%). A total of 7.88% of CU were positive for both amyloid-PET and tau-PET. Frequency of biologically defined AD increased with age (OR 1.14; p < 0.0001) and frequency of APOE ε4 allele carriers (single ε4: OR 3.82; p < 0.0001; double ε4: OR 17.55, p < 0.0001). CONCLUSION: Whereas we observed strong, but not complete, agreement between clinically defined probable AD dementia and biomarker positivity for both β-amyloid and tau, we also observed that biologically defined AD was not rare in CU elderly. Abnormal tau-PET was almost exclusively observed in individuals with abnormal amyloid-PET. Our results highlight that even in tertiary care memory clinics, detailed evaluation by dementia specialists systematically underestimates the frequency of biologically defined AD and related entities. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that biologically defined AD (abnormal amyloid PET and tau PET) was observed in 85.2% of people with clinically defined AD and 7.88% of CU elderly.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Therriault J, Pascoal TA, Benedet AL, et al. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE ε4, and Cognitive Impairment. Neurology. 2020. PMID: 33443136. doi:10.1212/WNL.0000000000011416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。